Maricann Group Inc. Receives Health Canada Approval for Phase One of Canadian Expansion

TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI)(FRANKFURT:75M)(OTCQB:MRRCF)(“Maricann” or the “Company”), is pleased to announce that it has received all of the necessary approvals from Health Canada to commence cultivation in Phase One of the Company’s new, state-of-the-art grow facility in Langton, Ontario, Canada. This is Maricann’s third licence issued by Health Canada.

“The licensing of Phase One of our Canadian expansion is a major milestone for both our employees and shareholders. This facility could be built in the Arctic, or the equator and still replicate the exact same cannabis every time. Due to the control and automation platform, combined with a unique building envelope design from standard stock, pre-engineered steel and greenhouse components, our overall costs are reduced,” stated Ben Ward, CEO

The design of the facility is revolutionary, combining the best of indoor cultivation and greenhouse technology. We utilize natural sunlight in a completely controlled, sealed, and energy efficient cultivation environment. Our automated process allows us to reduce ongoing operational costs to create a meaningful cost advantage.

Ward continued: “Environment and genetics are the two most critical elements in the production of cannabis. Our new facility, combined with Rare Dankness Cannabis Cup award winning genetics, provides Maricann with the ability to supply a superior product to the market. We invested significantly in a new purpose-built facility, with an optimal work flow that complies with GMP production standards and Six Sigma operations. This will result in ongoing low cost production of a premium quality product. We plan to bring our experience and expertise with us globally in replication of this world leading facility, designed by our VP of Infrastructure, Jeff Ayotte.”    

Elements of the expansion include:

• Segmentation of cultivation rooms into 8,800 square feet, to create an optimal environment for each strain’s cultivation that can be individually controlled, mitigating risk in potential cross contamination with individual pressurization in each room;
• 1,550,000 litre cistern, recycling all water used in the facility through a seven layer organic biological pond, reducing waste water to less than 10,000 litres per year.
• R-38 Exterior building envelope
• Natural Gas co-generation electric facility to produce low cost electricity.
• Co2 scrubber, using the exhaust of the natural gas co-gen facility and boilers, cleaning and then using as a fertilizer for plants in the increase of Co2 in each cultivation room, instead of industry standard liquid Co2.
• Diffused glass roof, combined with supplemental LED lights to provide natural sunlight, and enhanced lumen penetration of the canopy.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada, and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, with a designed expected capacity of producing 95,000 kg (based on conservative estimates) of dry cannabis flower per year to support existing and future patient growth.

Forward Looking Information
Certain statements in this document, including, without limitation, statements with respect to the future designed production capacity of Maricann’s expanded facility and other subjects, contain forward-looking statements which can be identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “desires”, “will”, “should”, “projects”, “estimates”, “contemplates”, “anticipates”, “intends”, or any negative such as “does not believe” or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to its operations, expansion project and other future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. In the case of the Company’s expected designed production capacity for its expansion project facility, the expectations of management are based on the production results of its current facility adjusted to reflect the greater square footage of the expanded facility and on the designs and plans of the new facility and assumes it will be successfully completed, and operate as planned.  Management cautions readers that the assumptions relative to the future events, several of which are beyond Management’s control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; failure to obtain all necessary regulatory approvals; risks inherent to building and bringing into production new facilities;  uncertainties with respect to estimated production capacity based on designs and plans; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition and other risks identified in the Company’s latest annual information form and other disclosure documents filed under its profile at www.sedar.com. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Maricann, please visit our website at www.maricann.com

CONTACT INFORMATION

Investor Relations
Graham Farrell
Director of Investor Relations
graham@maricann.com
647-643-7665

Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274

European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen, Deutschland